New drug combo aims to shrink untreatable liver tumors
NCT ID NCT07209813
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study tests whether adding an experimental drug called GKL-006 to a standard procedure (TACE) can shrink liver tumors that cannot be surgically removed. About 48 adults with advanced liver cancer will receive either the combination or TACE alone. The main goal is to see how many patients' tumors shrink significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.